Didžioji Britanija -
anglų -
MHRA (Medicines & Healthcare Products Regulatory Agency)
oxaliplatin 100mg/20ml concentrate for solution for infusion vials
pfizer ltd - oxaliplatin - solution for infusion - 5mg/1ml
Didžioji Britanija -
anglų -
MHRA (Medicines & Healthcare Products Regulatory Agency)
oxaliplatin 200mg/40ml concentrate for solution for infusion vials
pfizer ltd - oxaliplatin - solution for infusion - 5mg/1ml
Singapūras -
anglų -
HSA (Health Sciences Authority)
eloxatin 5mgml concentrate for solution for infusion
sanofi-aventis singapore pte. ltd. - oxaliplatin - injection, solution, concentrate - 5mg/ml - oxaliplatin 5mg/ml
Airija -
anglų -
HPRA (Health Products Regulatory Authority)
irinotecan 20 mg/ml concentrate for solution for infusion
fresenius kabi oncology plc - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - 20 milligram(s)/millilitre - other antineoplastic agents; miltefosine
Didžioji Britanija -
anglų -
MHRA (Medicines & Healthcare Products Regulatory Agency)
campto 100mg/5ml concentrate for solution for infusion vials
pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml
Didžioji Britanija -
anglų -
MHRA (Medicines & Healthcare Products Regulatory Agency)
campto 40mg/2ml concentrate for solution for infusion vials
pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml
Didžioji Britanija -
anglų -
MHRA (Medicines & Healthcare Products Regulatory Agency)
campto 300mg/15ml concentrate for solution for infusion vials
pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml
Airija -
anglų -
HPRA (Health Products Regulatory Authority)
irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion
accord healthcare ireland ltd. - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - 20 milligram(s)/millilitre - other antineoplastic agents; irinotecan
Airija -
anglų -
HPRA (Health Products Regulatory Authority)
campto 20 mg/ml concentrate for soln for inf
pfizer limited - irinotecan hydrochloride trihydrate - concentrate for soln for inf - 20 mg/ml - other antineoplastic agents
Izraelis -
anglų -
Ministry of Health
irinotecan hcl seacross 20 mgml
a.l. medi-market ltd. - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg / 1 ml - irinotecan - irinotecan hcl seacross is indicated for the treatment of patients with metastatic colorectal cancer: in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. for the treatment of patients with small cell lung cancer. for the treatment of patients with gastric cancer. irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil for the first-line treatment of patients with metastatic pancreatic adenocarcinoma